Clene Inc.

Clene Inc. is a clinical-stage biotechnology company focused on the development of nanotherapeutics to address neurodegenerative diseases. The primary function of Clene Inc. is to innovate in the realm of medicine by pioneering new treatments that utilize nanocrystal technology aimed at improving cellular energy efficiency in diseased tissue. This approach is designed to tackle some of the most pressing medical challenges seen in therapeutic areas such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). With its proprietary platform technology, Clene Inc. plays a significant role in the biopharmaceutical industry by seeking to deliver transformational therapies that address unmet needs in neurology. As a frontier company in biotechnology, Clene continues to push boundaries on how diseases affecting the nervous system are treated, contributing to advances in medical science and offering new hope for patients worldwide. The company is based in North America and actively engages in research and development to bring its innovative therapies closer to commercialization and clinical application.